TIBER CREEK GROUP for JAZZ PHARMACEUTICALS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Appropriations issues related H.R. 4356/S. 2599 - the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2022, pertaining to FDA enforcement of non-FDA approved CBD products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| EMILY KIRLIN | — |
| MATTHEW LEFFINGWELL | — |
| TIMOTHY A MOLINO | — |
Medical/Disease Research/Clinical Labs MED
Issues related to the FDA and S. 3032 - the FDA STATES Act (115th Congress), and Health and Human Services pertaining to CBD policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| EMILY KIRLIN | — |
| MATTHEW LEFFINGWELL | — |
| TIMOTHY A MOLINO | — |
Health Issues HCR
Issues related to the FDA and S. 3032 - the FDA STATES Act (115th Congress), and Health and Human Services pertaining to CBD policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| EMILY KIRLIN | — |
| MATTHEW LEFFINGWELL | — |
| TIMOTHY A MOLINO | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.